Motexafin lutetium is a texaphyrin, developed by Pharmacyclics Inc. (proposed trade names Lutrin, Antrin and Optrin)
It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease , 2002
It is photoactivated by 732 nm light which allows greater depth of penetration.
Clinical trials Phase II clinical trials were in progress in 1999.Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT , 1999
A phase I trial for prostate cancer reported in 2009.
As of 2017, this drug is no longer being developed.
See also Motexafin gadolinium
References